Yesafili

Yesafili (aflibercept) is a biosimilar intravitreal injection used to treat retinal conditions like wet age-related macular degeneration. It helps reduce abnormal blood vessel growth in the eye. This EU-approved treatment offers a cost-effective alternative to reference products. Suitable for patients seeking reliable eye care solutions.

Yesafili (aflibercept) is used to treat wet age-related macular degeneration (AMD), a condition causing vision loss in older adults. It is also prescribed for diabetic macular edema and macular edema following retinal vein occlusion. The medication helps stabilize vision by targeting vascular endothelial growth factor (VEGF). Patients with these retinal disorders may benefit from its anti-angiogenic properties.

Yesafili works by binding to VEGF, a protein that promotes abnormal blood vessel growth in the retina. This action helps reduce swelling and leakage in the macula, preserving central vision. Patients may notice improved clarity or stability in their vision over time. The effects are typically observed after regular intravitreal injections as prescribed by a healthcare provider.

Yesafili is administered as an intravitreal injection, requiring sterile conditions and professional handling. Patients should inform their doctor of any eye infections, inflammation, or recent eye surgeries. Regular eye exams are recommended to monitor treatment progress and detect any changes. Avoid rubbing the eye or exposing it to contaminants post-injection.

Limited data exists on drug interactions with aflibercept, as it acts locally in the eye. However, caution is advised when combining with other intravitreal therapies or anticoagulants. Patients using blood thinners should discuss risks with their healthcare provider. No significant systemic interactions are reported, but always disclose all medications to your doctor.